Press Releases

Investors

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arrowhead Presents Data on DPC System at TIDES 2012
Delivery polymer provides dramatic reduction in effective dose of Cholesterol-conjugated siRNA
View HTML
Toggle Summary Arrowhead Presents Data on DPC System and Hepatitis B Program at CLINAM 2012
Preclinical studies show substantial reduction of serum HBsAg, HBV DNA and dramatically decreased HBV RNA and DNA in liver
View HTML
Toggle Summary Arrowhead Reports Fiscal 2012 Second Quarter Financial Results
Arrowhead Reports Fiscal 2012 Second Quarter Financial Results PASADENA, Calif. — May 8, 2012 — Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in RNA therapeutics and obesity, today announced financial results for its fiscal 2012 second quarter ended
View HTML
Toggle Summary Arrowhead to Present at Series of Upcoming Scientific Conferences
Data Highlights Results Demonstrating Effectiveness of DPC siRNA Delivery System and Path to the Clinic for siRNA-based Hepatitis B Treatment
View HTML
Toggle Summary Arrowhead to Report Fiscal 2012 Second Quarter Financial Results
Conference Call Scheduled for Tuesday, May 8, 2012
View HTML
Toggle Summary Arrowhead Research Corporation Acquires Alvos Therapeutics and Proprietary Library of Targeting Peptides
Pioneer in targeting for tumors and tumor vasculature in humans
View HTML
Toggle Summary Arrowhead Releases White Paper on Hepatitis B Virus and Potential RNAi Treatment
Arrowhead Releases White Paper on Hepatitis B Virus and Potential RNAi Treatment PASADENA, Calif. — March 7, 2012 — Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in RNA therapeutics and obesity, announced today that it has released a white paper
View HTML
Toggle Summary Arrowhead Research Corporation and Axolabs GmbH Enter into Strategic Alliance and Master Services Agreement for RNAi Therapeutics
Arrowhead Research Corporation and Axolabs GmbH Enter into Strategic Alliance and Master Services Agreement for RNAi Therapeutics PASADENA, Calif. — March 5, 2012 — Arrowhead Research Corporation, a nanomedicine company with development programs in RNAi therapeutics and obesity, and Axolabs GmbH, a
View HTML
Toggle Summary Arrowhead Announces Patent Issuance Covering siRNA Inhibitors of HIF-2α (EPAS1)
Arrowhead Announces Patent Issuance Covering siRNA Inhibitors of HIF-2α (EPAS1) PASADENA, Calif. — February 29, 2012 — Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in RNA therapeutics and obesity, announced today that the United States Patent and
View HTML
Toggle Summary Arrowhead Reports Fiscal 2012 First Quarter Financial Results
Arrowhead Reports Fiscal 2012 First Quarter Financial Results PASADENA, Calif. — February 9, 2012 — Arrowhead Research Corporation (NASDAQ: ARWR) , a nanomedicine company with development programs in oncology and obesity, today announced financial results for its fiscal 2012 first quarter ended
View HTML